European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI)

被引：291

作者：

Bauer, M. P. ^{[2
]}

Kuijper, E. J. ^{[1
]}

van Dissel, J. T. ^{[2
]}

机构：

[1] Leiden Univ, Med Ctr, Ctr Infect Dis, Dept Med Microbiol, NL-2300 RC Leiden, Netherlands

[2] Leiden Univ, Med Ctr, Ctr Infect Dis, Dept Infect Dis, NL-2300 RC Leiden, Netherlands

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2009年 / 15卷 / 12期

关键词：

Clostridium difficile; guidelines; treatment; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; INTRAVENOUS IMMUNOGLOBULIN; PSEUDOMEMBRANOUS COLITIS; ORAL VANCOMYCIN; SACCHAROMYCES-CEREVISIAE; ANTIBODY-RESPONSE; FUSIDIC ACID; RISK-FACTORS; TOXIN-A;

D O I：

10.1111/j.1469-0691.2009.03099.x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Clostridium difficile infection (CDI) is a potentially fatal illness with an increasing incidence worldwide. Despite extensive ongoing research into CDI treatment, management of CDI still poses important problems, such as a high propensity to relapse and refractoriness to treatment, especially when there is an ileus and oral drugs cannot be adminstered. This guideline evaluates the available literature, discusses criteria for disease severity and provides recommendations for CDI treatment, indicating level of evidence and strength of recommendation.

引用

页码：1067 / 1079

页数：13

共 81 条

[1] Recurrent Clostridium difficile colitis:: Case series involving 18 patients treated with donor stool administered via a nasogastric tube
Aas, J
Gessert, CE
Bakken, JS
[J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) : 580 - 585
[2] Comparison of clinical and microbiological response to treatment of Clostridium difficile associated disease with metronidazole and vancomycin
Al-Nassir, Wafa N.
Sethi, Ajay K.
Nerandzic, Michelle M.
Bobulsky, Greg S.
Jump, Robin L. P.
Donskey, Curtis J.
[J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 (01) : 56 - 62
[3] Emergence of reduced susceptibility to metronidazole in Clostridium difficile
Baines, Simon D.
O'Connor, Rachael
Freeman, Jane
Fawley, Warren N.
Harmanus, Celine
Mastrantonio, Paola
Kuijper, Ed J.
Wilcox, Mark H.
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (05) : 1046 - 1052
[4] BAKKEN S, 2007, 45 ANN M INF DIS SOC
[5] BARTLETT JG, 1980, GASTROENTEROLOGY, V78, P431
[6] BARTLETT JG, 1984, REV INFECT DIS, V6, pS235
[7] Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii
Bassetti, S
Frei, R
Zimmerli, W
[J]. AMERICAN JOURNAL OF MEDICINE, 1998, 105 (01) : 71 - 72
[8] Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea
Beales, ILP
[J]. GUT, 2002, 51 (03) : 456 - 456
[9] Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial
Besselink, Marc G. H.
van Santvoort, Hjalmar C.
Buskens, Erik
Boermeester, Marja A.
van Goor, Harry
Timmerman, Harro M.
Nieuwenhuijs, Vincent B.
Bollen, Thomas L.
van Ramshorst, Bert
Witteman, Ben J. M.
Rosman, Camiel
Ploeg, Rutger J.
Brink, Menno A.
Schaapherder, Alexander F. M.
Dejong, Cornelis H. C.
Wahab, Peter J.
van Laarhoven, Cees J. H. M.
van der Harst, Erwin
van Eijck, Casper H. J.
Cuesta, Miguel A.
Akkermans, Louis M. A.
Gooszen, Hein G.
[J]. LANCET, 2008, 371 (9613) : 651 - 659
[10] TREATMENT OF RECURRENT CLOSTRIDIUM-DIFFICILE COLITIS WITH LACTOBACILLUS GG
BILLER, JA
KATZ, AJ
FLORES, AF
BUIE, TM
GORBACH, SL
[J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1995, 21 (02) : 224 - 226

← 1 2 3 4 5 6 7 8 9 →